(Updates with UBS' response to a request for comment.)
The Federal Reserve said Friday it has terminated its enforcement actions with UBS Group (UBS), Credit Suisse and their subsidiaries.
UBS declined to comment to.
Price: $45.46, Change: $-0.89, Percent Change: -1.92%
Illumina's (ILMN) mid-teens clinical growth appears sustainable over the next one to two years, driven largely by oncology testing and screening applications, as the company sees building clinical momentum and fading competitive concerns, RBC said in a Thursday note.With clinical markets now comprising over 50% of the company's sales, growth has accelerated to 20% in each of the past two quarters, supported by robust growth forecasts for Illumina's oncology customers, according to the note.Illumina sees fading competitive concerns with Roche's Axelios 1 sequencing update seeing mixed response, RBC said, adding that it did not see any updates at Roche's investor event earlier this week to change the narrative.Additionally, RBC said that the weakness Illumina is seeing in academic demand is an industry-wide problem and that several new product launches should enable demand to at least flatten by next year, which will be enough to meet or exceed Wall Street forecasts.RBC has an outperform rating on the company, with a $170 price target.Price: $139.93, Change: $-3.31, Percent Change: -2.31%
Gray Media (GTN) and E.W. Scripps (SSP) closed their swap of television stations across five markets in four US states, the companies said Friday.The cash-free, even exchange, announced in July, includes stations in Lansing, Michigan; Lafayette, Louisiana; Colorado Springs and Grand Junction in Colorado; and Twin Falls, Idaho.Shares of Gray Media fell 1.2% in Friday trading, and E.W. Scripps dropped 2.3%.Price: $4.12, Change: $-0.05, Percent Change: -1.20%
Danaher (DHR) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.Danaher is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.RBC Capital Markets resumed coverage on Danaher, with an outperform rating and a $200 price target.Shares of Danaher were down 1.1% in Friday afternoon trading.Price: $162.75, Change: $-1.79, Percent Change: -1.09%